| Bhavana C Anand, MD | |
|
1560 Beam Ave, Suite F, Maplewood, MN 55109 | |
| (651) 340-1445 | |
| (651) 340-5421 |
| Full Name | Bhavana C Anand |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 1560 Beam Ave, Maplewood, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932343969 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 57508 (Minnesota) | Primary |
| Entity Name | My Medical Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215344742 PECOS PAC ID: 4587986112 Enrollment ID: O20141209001955 |
News Archive
Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.
"Morocco has made great strides in improving maternal health in recent years, decreasing its maternal mortality ratio by over 60 percent since 1990," but "a wide maternal health gap" exists between women in urban and rural areas, where deliveries generally are attended by an experienced yet untrained family member, Women's eNews reports.
Four new studies investigating the effects of supplements, eating habits and physical activity and how they can affect various aspects of health during pregnancy are being presented at NUTRITION 2021 LIVE ONLINE.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bhavana C Anand, MD 1560 Beam Ave, Suite F, Maplewood, MN 55109 Ph: (651) 340-1445 | Bhavana C Anand, MD 1560 Beam Ave, Suite F, Maplewood, MN 55109 Ph: (651) 340-1445 |
News Archive
Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.
"Morocco has made great strides in improving maternal health in recent years, decreasing its maternal mortality ratio by over 60 percent since 1990," but "a wide maternal health gap" exists between women in urban and rural areas, where deliveries generally are attended by an experienced yet untrained family member, Women's eNews reports.
Four new studies investigating the effects of supplements, eating habits and physical activity and how they can affect various aspects of health during pregnancy are being presented at NUTRITION 2021 LIVE ONLINE.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 1 days ago